VTE
 | Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity CME, CPE Rachel P. Rosovsky, MD, MPH and Stephan Moll, MD | |
| Release Date: January 30, 2023 Expiration Date: January 30, 2024 | ||
In this activity, two experts discuss direct oral anticoagulants (DOACs) in patients with VTE and obesity and review updated guidelines. They will discuss safety and appropriate dosing strategies for patients with a certain BMI, as well as the use of prophylaxis. The program will conclude with a discussion on the use of DOACs in patients after bariatric surgery. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. | ||
| Begin, Earn CreditView Only, No Credit | ||
 | VTE Pathophysiology and DOAC Pharmacokinetics in Obesity CME, CPE Daniel M. Witt, PharmD, FCCP, BCPS | |
| Release Date: March 31, 2022 Expiration Date: March 31, 2023 | ||
Join Dr. Witt as he explains how to optimize DOAC pharmacokinetics in patients with obesity. Topics include hemostasis, the impact of obesity on clot formation, and the effects of obesity on DOAC absorption, distribution, metabolism, and excretion. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. | ||
| View Only, No Credit | ||
 | Improving Care Disparities for Black Americans in Mississippi with Venous Thromboembolism: The Role of Care Transitions in Critical Access Hospitals CME, CPE, CNE Charles V. Pollack, Jr., MD, FACEP, FAAEM, FAHA, FACC, FESC, FCPP; DeGail J. Hadley, DO; Cynthia Harrington, DNP, APRN, FNP-BC, PMHNP-BC, NEd, MT(ASCP); Elizabeth Hood, PharmD | |
| Release Date: June 02, 2021 Expiration Date: June 02, 2022 | ||
This activity is designed to educate clinicians on how to reduce care disparities and health outcomes for Black Americans in rural Mississippi with a venous thromboembolism (VTE) diagnosis, as they make the transition from a Critical Access Hospital (CAH) back into their own communities on oral anticoagulants. This activity was previously presented as a live webinar with Q&A during May 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.5 contact hours of credit and may not re-submit for credit previously awarded. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance. This program would not have been possible without the support and dedication of resources from the Mississippi State Medical Association, Mississippi Hospital Association, National Blood Clot Alliance, and the Mississippi Business Group on Health. | ||
| View Only, No Credit | ||